Skip to main content
. 2013 Sep;5(Suppl 4):S389–S396. doi: 10.3978/j.issn.2072-1439.2013.07.10

Table 3. Results of six new agents in advanced NSCLC as monotherapy and in combination with platinum analogues (Pt) (10).

Agent Complete response + Partial response Complete response + Partial response combination with (Pt) analogues
Vinorelbine >15% 30-45% (C)
Gemcitabine >15% 28-54% (C)
Paclitaxel >15% 27-44% (C)
Docetaxel >15% 25-62% (C)
Docetaxel >15% 26-51% (Cb)
Irinotecan >15% 50% (C)
Pemetrexed <15% 30.6% (C)